Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05669716
Other study ID # 10001196
Secondary ID 001196-DA
Status Recruiting
Phase
First received
Last updated
Start date February 3, 2023
Est. completion date July 1, 2024

Study information

Verified date April 24, 2024
Source National Institutes of Health Clinical Center (CC)
Contact NIDA IRP Screening Team
Phone (800) 535-8254
Email researchstudies@nida.nih.gov
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: The use of electronic cigarettes (vaping) has increased among adolescents over the past decade. Vaping raises many health concerns. People who vape inhale toxic chemicals. Vaping is also linked with mental health issues, such as depression and suicide risk. In one survey, 85% of young adults reported that they used both vaping and tobacco products; the primary reason they cited for using these products was stress. Objective: This natural history study will survey adolescents and their parents about their attitudes toward vaping. Eligibility: People aged 13 to 17, including those who vape; those who once vaped; and those who have never vaped. Parents of people aged 13 to 17 who are known or suspected of vaping are also needed. Design: Participants will take a survey. They will use their own smartphone, computer, or tablet to answer questions. The survey will take about 20 minutes. Their answers will be anonymous. Teenage participants will answer questions on different topics: Vaping habits, such as when and how they vape. Drug use, including nicotine, cannabis, and alcohol. Mood issues, such as depression, anxiety, and stress. Social influences on vaping, including perceived attitudes of parents and peers. Other leisure habits, including online gaming and use of social media. Parents will answer similar questions. A phone number and links will be given to participants who need help for suicidal thoughts. Other links will be given to those who want help with parenting resources or aids to quit vaping. Participants may be invited to take part in an 8-week course on mindfulness-based stress reduction. Participants who finish the survey will receive $10. ...


Description:

Study Description: This protocol will explore characteristics of adolescents who vape and the attitudes of adolescents and parents of adolescents who vape towards adolescent vaping, focusing on the Baltimore area. Hypotheses: (Adolescent) Currently vaping adolescents will not view vaping as a problem for which they seek help and will have more mental health symptoms than non-vaping adolescents, while non-vaping adolescents will view vaping more negatively with formerly vaping adolescents scoring between the currently vaping and non-vaping adolescent groups. (Parent) Parents who vape will be more likely to approve of their adolescent s vaping than non-vaping parents. Objectives: Primary Objective: To characterize adolescent vaping patterns, overall drug use, perceived stress, and awareness of mindfulness meditation. Secondary Objectives: To characterize the mental health symptoms of currently vaping, formerly vaping and non-vaping adolescents, and to characterize parent attitudes towards their adolescent s vaping. Endpoints: Primary Endpoint: An adequate description of adolescent vapers habits and attitudes towards their vaping. Secondary Endpoints: An adequate comparison of adolescent vapers, former vapers and non-vapers and of parental attitudes towards adolescent vapers.


Recruitment information / eligibility

Status Recruiting
Enrollment 1600
Est. completion date July 1, 2024
Est. primary completion date July 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 13 Years and older
Eligibility - INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must: Be an adolescent age 13-17, OR an adult who identifies as parenting an adolescent aged 13-17 whom they know/suspect is vaping. While we are including adolescents who do not vape in addition to those who do vape, we are only including parents of adolescents who do (or are suspected to) vape because it is this population that is most directly relevant to the upcoming MBSR study, and it is the attitudes of these parents that have most direct practical significance on adolescent vaping. All participants must be willing to complete the survey to the end. EXCLUSION CRITERIA: Non-English speakers cannot participate in this study. Justification: The questionnaires from which the survey is constructed are not all validated in languages other than English. We do not have the resources to translate the consent and surveys. Those who cannot demonstrate understanding of the purpose of the survey by answering questions after a brief explanation will be excluded. Justification: The ability to understand the purpose of the survey is required in order to provide informed consent to participate and to be able to provide meaningful answers to the survey questions.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institute on Drug Abuse Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Attitude toward vaping An adequate description of adolescent vapers habits and attitudes towards their vaping. at time of survey
Secondary characteristics of parents of teens who vape parental attitudes towards adolescent vapers. at time of survey
Secondary comparison of vaping and non-vaping teens on mental health and other drug use An adequate comparison of adolescent vapers, former vapers and non-vapers on mental health and other drug use. at time of survey
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1